There is one clinical trial.
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based
on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis
of COVID-19 made by the medical team.
Primary Outcomes
Measure: Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team Time: Baseline (at admission)
Secondary Outcomes
Measure: Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission Time: Baseline (at admission)